Tweets
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns
Pregnancy in patients with systemic lupus erythematosus (SLE) continues to carry significantly elevated risks, with maternal mortality rates nearly five times higher than in the general population.
https://t.co/3G7Eftt0Kg https://t.co/X3SUl6FTHO
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/XNd8uYLQsJ
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
Upcoming Lupus Nephritis Pipeline
1. Gazyva (obinutuzumab) – due for FDA/EMA decision
2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN
3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/jEv2uvhkqK
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/QPKLqTQfPj
Links:
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
FDA has approved a SC autoinjector of Benlysta (BEL) for use in pediatric lupus nephritis & pts > 5rs of age for SLE and active LN. BEL SC dosing for Pediatric SLE: 200 mg qwk (>40 kg) or 200 mg EOW (q2wk) if 15-40 kg. https://t.co/zrskHdw9Jx https://t.co/jkqygmfJPv
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
MRI Lesions in Early axSpA vs Non-axSpA
Dr. Adela Castro reports on abstract OP0310 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/sVWpyUT1IY https://t.co/wzobROoH1K
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
JAK Inhibitors: The Latest from the JAK-pot Study
Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory https://t.co/KiOZuphQTx
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyopathic form with distinctive skin findings & rapidly progressive interstitial lung dz. Rx includes Hi dose steroids, calcineurin inhib & IV CTX (maybe JAKi, MMF)
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
AI Advances axSpA Diagnosis with Multimodal MRI
Dr. Bella Mehta reports on abstract OP0307 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/fpgwQniSA5 https://t.co/EbT9v821xb
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
Complex-to-Manage PsA: The GRAPPA Framework and Definition
Dr. Nelly Ziade discusses abstract OP0175 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/cyDUCGU6Pc https://t.co/jdsTEB3Rqw
Links:
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
All Rheumatoid Arthritis is Not the Same
Dr. Jonathan Kay reviews abstracts OP0323 and OP0328 from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/rbK3Y1NHVI https://t.co/eYPdbx87kt
Links:
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
Assessment of Peripheral Arthritis in Spondyloarthritis
Dr. Antoni Chan talks with Dr. Dafne Capelusnik about abstract POS0257 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/E6l6qvNnox https://t.co/gLbMjF406q
Dr. John Cush @RheumNow ( View Tweet )
9 months 3 weeks ago
